[SCHEDULE 13G] Beta Bionics, Inc. SEC Filing
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander disclosed a shared, non‑sole beneficial ownership of 2,286,728 shares of Beta Bionics, Inc. common stock, representing 5.3% of the class. The filing on a Schedule 13G indicates the stake is reported under passive ownership rules, with no sole voting or dispositive power claimed and shared voting and dispositive power of 2,286,728 shares. Addresses and citizenships of the reporting persons are provided and a Joint Filing Agreement is attached.
- Disclosure of a material passive stake: Reporting persons publicly disclosed an aggregate 5.3% ownership, improving transparency for investors
- Joint Filing Agreement attached: Exhibit I documents coordination among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander
- None.
Insights
TL;DR: A passive 5.3% stake by Millennium and related parties is disclosed; material sized position, but no control claimed.
The Schedule 13G reports an aggregate 2,286,728-share position in Beta Bionics, equal to 5.3% of outstanding common stock, held with shared voting and dispositive power and no sole power. Filing under Schedule 13G signals passive intent rather than an attempt to influence control. For investors, the key takeaway is the emergence of a sizable institutional holder with voting influence exercised jointly through related entities, documented via a Joint Filing Agreement.
TL;DR: Reporting persons disclose shared control over a >5% stake while explicitly denying sole control or intent to change issuer control.
The document shows coordinated reporting by Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander, each claiming shared voting and dispositive power over the same 2,286,728 shares. The certification states the securities were not acquired to influence control. The Joint Filing Agreement (Exhibit I) formalizes the joint filing relationship among the parties.